Krahn Chemie distributes EVA of Braskem
Advertisement
Early this year, Braskem Europe BV granted the Hamburg distributor Krahn Chemie GmbH the sales rights for ethylene vinyl acetate copolymers (EVA) of the Brazilian holding company Braskem S.A..
The EVA products known under the brand name EVATENO® are marketed by Krahn Chemie GmbH in the segments adhesives, cables, shoes and compounds throughout all of Europe, with the exception of Great Britain and Italy.
Types are currently being offered with a VA content of 19 - 28% and a MFI of 2.5 - 150 g/10min. Higher MFI are currently being developed and shall be introduced midyear.
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Grace Opens Office in Southern Australia
Cargill and Topchim: Strategic partnership to produce a sustainable line of products in Brazil
Avecia completes sales of its Pharmaceuticals business unit

New research introduces 'pause button' for boiling
Linde to build on-site facility for Dutch steelworks

Elster Kromschröder - Osnabrück, Germany
Akzo Nobel to acquire ICI's German industrial wood finishes business
Sumitomo Chemical Expands Production Capacity for Resorcinol
Millipore Launches Major Expansion of Life Sciences Facility in Danvers

Organic insect deterrent for agriculture - Biodegradable crop protection products without risks or side effects
US FDA approves Novartis' Starlix®
